Cangrelor

Drug Profile

Cangrelor

Alternative Names: AR-C 69931; AR-C69931MX; Kengreal; Kengrexal

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Adenine nucleotides; Antiplatelets; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease; Coronary thrombosis
  • Phase I Acute coronary syndromes

Most Recent Events

  • 27 Aug 2016 Efficacy data from pooled analysis of CHAMPION PLATFORM, CHAMPION PCI and CHAMPION PHOENIX trial in Coronary artery disease presented at the Annual Congress of the European Society of Cardiology (ESC Congress 2016)
  • 22 Jun 2016 Chiesi USA and Chiesi Farmaceutici acquired multinational rights to cangrelor (Kengreal®) from The Medicines Company
  • 04 May 2016 The Medicines Company plans a phase I trial for Thrombosis (Prevention, In neonates) in USA (IV) (NCT02765633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top